Business Context and Reporting Period
This Form 8-K is filed by Predictive Oncology Inc. (not Axe Compute Inc.) on July 18, 2025. The report addresses the retrospective revision of the Company's historical consolidated financial statements for the fiscal year ended December 31, 2024, and 2023. The filing reclassifies the "Eagan Business" (automated medical fluid disposal products, including the STREAMWAY product line) as discontinued operations following its sale to DeRoyal Industries, Inc., which closed in March 2025.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document serves solely to announce the accounting reclassification of the Eagan Business segment. Detailed financial figures resulting from this reclassification are contained in Exhibit 99.1, which is incorporated by reference but not included in the provided text.
Material Changes Versus Prior Period
- Discontinued Operations: The Eagan Business, previously reported as a continuing operating segment, is now presented as discontinued operations for all periods presented in the 2024 Form 10-K and subsequent filings.
- Asset Sale: The Company sold and assigned assets and liabilities related to the Eagan Business to DeRoyal Industries, Inc. under an agreement dated March 14, 2025.
- Reporting Scope: This filing updates Part I, Item 1 (Business), Part II, Item 7 (MD&A), and Part II, Item 8 (Financial Statements) of the 2024 Form 10-K to reflect these changes.
Guidance, Outlook, and Risks
The filing explicitly states that it does not update Management's Discussion and Analysis regarding forward-looking statements, risks, or trends occurring after the 2024 Form 10-K, except as required to reflect the discontinued operations. Investors are directed to the Q1 2025 Form 10-Q and subsequent 8-K filings for updated expectations and developments. The filing clarifies that it is not a restatement of the 2024 Form 10-K but a retrospective revision to align with the discontinued operations criteria met in Q1 2025.
Investor Verification Checklist
- Verify the specific financial impact of the Eagan Business reclassification by reviewing Exhibit 99.1 attached to this filing.
- Confirm the final sale price and terms of the asset purchase agreement with DeRoyal Industries, Inc. in the March 2025 8-K filing.
- Review the Q1 2025 Form 10-Q for the first presentation of the Eagan Business as discontinued operations in interim financial statements.
- Ensure the company name is correctly identified as Predictive Oncology Inc. (Ticker: POAI), as the input metadata referenced "Axe Compute Inc." which is not the registrant in this document.